Última actualización 3 de septiembre de 2026
Key finding
Dapagliflozin was associated with reduction of LA volume index (−2.0 ± 9.0 vs. 0.03 ± 8.6, p = 0.002).
This study evaluated the effects of dapagliflozin on diastolic function and exercise capacity in patients with type 2 diabetes and stage B heart failure, finding significant improvements in certain cardiac measures and exercise capacity.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of dapagliflozin on diastolic function and exercise capacity in patients with type 2 diabetes and stage B heart failure, finding significant improvements in certain cardiac measures and exercise capacity.
These findings suggest that dapagliflozin may provide beneficial effects beyond glucose control in patients with type 2 diabetes and early heart failure. By improving diastolic function and exercise capacity, dapagliflozin could enhance the quality of life and potentially reduce the risk of heart failure progression in this patient population.
The study had a limited sample size. Results may not be generalizable to all populations with heart failure. The follow-up duration was only 6 months.
Published in
Publication details and source links for this paper.
Thomas HM, Amera H, Cheng HS, et al. Dapagliflozin improves diastolic function and exercise capacity in patients with T2DM and stage B heart failure. Cardiovascular Diabetology. 2025;24:232. doi:10.1186/s12933-025-02796-4
Dapagliflozin reduced left atrial volume index by −2.0 mL/m² (p = 0.002).
Dapagliflozin decreased average E/e' by −0.1 (p < 0.001).
Dapagliflozin improved left atrial reservoir strain by 1.8 (p = 0.02).
Dapagliflozin increased 6-minute walk distance by 17 m (p = 0.001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dapagliflozin 10 mg/day and 6-minute walk distance, Average E/e', Decrease in Abdominal Volume Index, and 2 more.
This study contributes evidence to
Primary intervention
Dapagliflozin 10 mg/day
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
5
Evidence pairs
56
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Core evidence
The primary outcomes reported in this study.
Dapagliflozin 10 mg/day → 6-minute walk distance
Dapagliflozin 10 mg/day → 6-minute walk distance
Dapagliflozin 10 mg/day → Decrease in Abdominal Volume Index
Dapagliflozin 10 mg/day → Decrease in Abdominal Volume Index
Dapagliflozin 10 mg/day → Global longitudinal strain
Dapagliflozin 10 mg/day → Global longitudinal strain
Dapagliflozin 10 mg/day → Left atrial reservoir strain (LASr_ED)
Dapagliflozin 10 mg/day → Left atrial reservoir strain (LASr_ED)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Dapagliflozin 10 mg/day and Cardiovascular Outcomes, Dapagliflozin 10 mg/day and Decrease in Abdominal Volume Index.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Cardiovascular Outcomes
Measures Cardiovascular Outcomes as a key outcome.
All studies on Dapagliflozin 10 mg/day
Contributes to Dapagliflozin 10 mg/day evidence base.
All studies measuring Decrease in Abdominal Volume Index
Measures Decrease in Abdominal Volume Index as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Dapagliflozin 10 mg/day appears to improve 6-minute walk distance.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
6-minute walk distance
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Dapagliflozin 10 mg/day appears to improve average e/e'.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Average E/e'
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Dapagliflozin 10 mg/day appears to improve decrease in abdominal volume index.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Decrease in Abdominal Volume Index
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Dapagliflozin 10 mg/day appears to improve left atrial reservoir strain (lasr_ed).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Left atrial reservoir strain (LASr_ED)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
